Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) maintains global leadership in blood safety through its INTERCEPT Blood System, a pathogen inactivation platform protecting transfusion medicine worldwide. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical advancements, and operational developments.
Access timely reports on FDA clearances, European CE marks, and partnerships with blood centers across 40+ countries. Track progress in platelet and plasma treatment adoption, red blood cell system trials, and international expansion efforts. Our curated news collection ensures you never miss critical updates about this biomedical innovator.
Key coverage areas include quarterly financial results analysis, peer-reviewed study publications, manufacturing capacity expansions, and strategic collaborations with global health organizations. All content is verified through primary sources including company filings and official statements.
Bookmark this page for streamlined access to CERS developments impacting transfusion safety standards. Combine real-time alerts with historical context to understand Cerus' role in combating emerging bloodborne pathogens through cutting-edge nucleic acid targeting technology.
Cerus Corporation (CERS) reported a robust Q4 2021 with total revenues of $50.1 million, up 49% year-over-year, driven by a 41% increase in product revenues to $39.9 million. The full-year revenue reached $159.5 million, a 40% increase from 2020. The company reiterated its 2022 product revenue guidance of $157-$164 million, indicating expected growth of 20%-25%. Notably, government contract revenues surged by 90% to $10.2 million in Q4. However, net loss narrowed to $9.1 million, down from $14.4 million in Q4 2020.
Cerus Corporation (NASDAQ: CERS) will release its fourth quarter and full-year 2021 financial results on February 22, 2022, post-market close. A conference call will follow at 4:30 P.M. ET, providing insights into the company’s performance and future outlook. Investors can access the live webcast on Cerus’ Investor Relations page or by calling U.S. (866) 235-9006 or international (631) 291-4549.
Additionally, a replay will be available post-call through March 8, 2022.
Cerus Corporation (CERS) announced its participation in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference and the 11th Annual SVB Leerink Global Healthcare Conference. Vivek Jayaraman, COO, will present on February 16 at 9:00 a.m. EST, while CFO Kevin Green will participate on February 18 at 12:00 p.m. EST. The events are for BTIG clients, and webcasts can be accessed via Cerus' investor relations webpage. Cerus focuses on safeguarding the blood supply globally, offering the INTERCEPT Blood System, which has CE and FDA approvals for pathogen reduction.
Cerus Corporation (CERS) announced preliminary product revenues for Q4 2021 at
Cerus Corporation (NASDAQ: CERS) announced that CFO Kevin D. Green will participate in the Stephens Annual Investment Conference on December 3, 2021, at 2:00 p.m. ET in Nashville, Tennessee. A live webcast will be accessible on the Cerus Investor Relations page, with a replay available for about two weeks post-event. Cerus is focused on safeguarding the global blood supply, offering technologies like the INTERCEPT Blood System, which has CE Mark and FDA approval for pathogen reduction in platelets and plasma. For details, visit www.cerus.com/ir.
On November 15, 2021, Cerus Corporation (CERS) will participate in the Stifel 2021 Virtual Healthcare Conference, featuring CEO William ‘Obi’ Greenman and CFO Kevin D. Green. The event is set for 4:40 p.m. ET, with a live webcast available on Cerus' Investor Relations page. Cerus is focused on ensuring blood safety, developing technologies like the INTERCEPT Blood System, which is approved for pathogen reduction in platelets and plasma. The company aims to lead in global blood products.
Cerus Corporation (CERS) reported strong financial results for Q3 2021, with total revenue of $42.1 million, a 44% increase year-over-year. Product revenue reached $36.1 million, up 53% compared to Q3 2020. The company raised its full-year 2021 product revenue guidance to a range of $127-129 million, anticipating a growth of 38-40% over the previous year. Despite operational expenses increasing to $35.6 million, net loss improved to $12.4 million from last year's $14.1 million. Cerus continues to see significant demand for the INTERCEPT Blood System.
Cerus Corporation (NASDAQ: CERS) will release its third quarter 2021 financial results on November 2, 2021, after market close. A conference call and webcast are scheduled for 4:30 PM ET on the same day, where management will discuss the financial results and provide a business overview. The INTERCEPT Blood System, the company's flagship product, remains the only pathogen reduction system with CE mark and FDA approval for platelets and plasma. A replay of the call will be available post-event until November 16, 2021.
Today, the FDA's final guidance on bacterial risk control for platelet collection and transfusion takes effect, promoting the INTERCEPT Blood System for platelets by Cerus (CERS) as a compliant pathogen reduction solution. This system not only addresses bacterial contamination—recognized as a major risk in the U.S.—but also inactivates a range of viruses and parasites. The guidance aims to enhance platelet safety and availability for transfusions across the U.S., marking a significant milestone in transfusion medicine, as INTERCEPT is currently the only FDA-approved measure for compliance.
Cerus Corporation (NASDAQ: CERS) will participate in the Society for the Advancement of Blood Management Annual Meeting from September 22-25, 2021. On September 23, Cerus will host a workshop discussing the clinical need for the INTERCEPT Fibrinogen Complex, featuring presentations from hospital customers. The INTERCEPT Blood System for Cryoprecipitation is FDA approved since November 2020, aimed at improving treatment of massive hemorrhage. Additionally, CMS has granted a New Technology Add-On Payment for the INTERCEPT Fibrinogen Complex.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
